In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is an American biotechnology company that is focused on developing and commercializing medicines for patients with a range of diseases, including eye ...

Regeneron and Illumina have joined a major ... of genotypic and phenotypic information ever assembled," claims the company. It will tap into Truveta's platform – based on electronic medical ...

This was the stock's second consecutive day of gains.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...